Intelligence / Healthtech / De Novo Grants / Fusmobile, Inc.
Approvalsnovel device granted (FDA De Novo)14 Nov 2025
Fusmobile, Inc.
14 Nov 2025: Novel device granted (FDA De Novo) · Neurolyser XR (NXR100). Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 14 Nov 2025
- Device
- Neurolyser XR (NXR100)
- Specialty
- Neurology
- Product Code
- SGN
- Country
- United States
- Location
- Alpharetta, GA
- Submitted
- 2025-04-25
- Reference
- DEN250015
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Fusmobile, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Fusmobile, Inc. in our registers.
More in Neurology
De Novo Grants
21 AugMatap Ii, LLCnovel device granted (FDA De Novo) · AvuluxApprovals8 MayNeurovalens Limitednovel device granted (FDA De Novo) · Modius SperoApprovals3 AprAutomated Imaging Diagnostics, LLCnovel device granted (FDA De Novo) · neuropacsApprovals6 OctPainchek Limited (Ltd.)novel device granted (FDA De Novo) · PainChek (PainChek Adult)Approvals20 AugQuantalx Neuroscience, Ltd.novel device granted (FDA De Novo) · Delphi-MD SystemApprovals17 JunTissium SAnovel device granted (FDA De Novo) · COAPTIUM Connect with TISSIUM LIGHTApprovals
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.